Date: 2015-03-31
Type of information: Financing round
Company: Atyr Pharma (USA - CA)
Investors: Sofinnova Ventures (France) undisclosed large institutional investor in the biotechnology industry, Federated Investors (USA - PA), Deerfield (USA - NY), Rock Springs Capital Management (USA - MD) EcoR1 Capital (USA - CA), Sphera Global Healthcare (Israel - USA - NY), two additional undisclosed institutional investors
Amount: $76 Million
Funding type: series E financing round
Planned used: aTyr Pharma plans to use the proceeds to further develop its pipeline and advance its lead program through clinical trials, including an ongoing Phase 1b/2 trial of Resolaris®, an investigational new drug representing aTyr’s first Physiocrine-based product candidate in the clinic. The funds will also support expansion of Resolaris®\' development to additional indications.
Others: * On March 31, 2015, aTyr Pharma, a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, announced the successful completion of a $76 million Series E financing led by new investors Sofinnova Ventures and an undisclosed large institutional investor in the biotechnology industry. Additional new investors taking part in this round of financing include certain funds and accounts advised by T. Rowe Price Associates, Inc.; Federated Investors, Inc.; Deerfield; Rock Springs Capital Management; EcoR1 Capital; Sphera Global Healthcare and two additional undisclosed institutional investors. Current venture capital investors and a current public investment fund also took part in the raise. Atyr Pharma also announced the addition of Srinivas Akkaraju, M.D., Ph.D., and general partner at Sofinnova Ventures to the board of directors in conjunction with the financing. Dr. Akkaraju, a physician-scientist with a successful track record in public company investing, brings with him more than 16 years of biopharmaceutical experience in both the private and public sectors. Dr. Akkaraju’s past and current board seats include Eyetech Pharmaceuticals, Intercept Pharmaceuticals, Seattle Genetics, Synageva BioPharma, ZS Pharma, Amarin, and Versartis.
Therapeutic area: Cancer - Oncology - Genetic diseases
